Literature DB >> 22791508

Remission induction in acute myeloid leukemia.

Eytan M Stein1, Martin S Tallman.   

Abstract

Inducing a complete remission (CR) in patients with acute myeloid leukemia is a prerequisite to long-term disease control with subsequent post-remission consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation. The use of 7 days of infusional cytarabine and 3 days of daunorubicin or idarubicin (7 + 3) has become the standard of care to induce CR, based on clinical trials conducted in the 1980s. Efforts to improve on the CR rate seen with the 7 + 3 regimen that translates into better overall patient survival have been disappointing. Here we review recent phase III studies of novel induction strategies that show promise in increasing the rate of CR and improving disease outcome.

Entities:  

Mesh：

Year:  2012        PMID： 22791508      PMCID： PMC4052975          DOI： 10.1007/s12185-012-1121-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  11 in total

1.  Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

Authors:  K R Rai; J F Holland; O J Glidewell; V Weinberg; K Brunner; J P Obrecht; H D Preisler; I W Nawabi; D Prager; R W Carey; M R Cooper; F Haurani; J L Hutchison; R T Silver; G Falkson; P Wiernik; H C Hoagland; C D Bloomfield; G W James; A Gottlieb; S V Ramanan; J Blom; N I Nissen; A Bank; R R Ellison; F Kung; P Henry; O R McIntyre; S K Kaan
Journal:  Blood       Date:  1981-12       Impact factor: 22.113

2.  Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

Authors:  Jerzy Holowiecki; Sebastian Grosicki; Sebastian Giebel; Tadeusz Robak; Slawomira Kyrcz-Krzemien; Kazimierz Kuliczkowski; Aleksander B Skotnicki; Andrzej Hellmann; Kazimierz Sulek; Anna Dmoszynska; Janusz Kloczko; Wieslaw W Jedrzejczak; Barbara Zdziarska; Krzysztof Warzocha; Krystyna Zawilska; Mieczyslaw Komarnicki; Marek Kielbinski; Beata Piatkowska-Jakubas; Agnieszka Wierzbowska; Malgorzata Wach; Olga Haus
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

3.  A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.

Authors:  Je-Hwan Lee; Young-Don Joo; Hawk Kim; Sung Hwa Bae; Min Kyoung Kim; Dae Young Zang; Jung-Lim Lee; Gyeong Won Lee; Jung-Hee Lee; Jae-Hoo Park; Dae-Young Kim; Won-Sik Lee; Hun Mo Ryoo; Myung Soo Hyun; Hyo Jung Kim; Young Joo Min; Yae-Eun Jang; Kyoo-Hyung Lee
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

4.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Authors:  Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

5.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Authors:  Sylvie Castaigne; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Dominique Bordessoule; Jean-Noel Bastie; Ollivier Legrand; Xavier Thomas; Pascal Turlure; Oumedaly Reman; Thierry de Revel; Lauris Gastaud; Noémie de Gunzburg; Nathalie Contentin; Estelle Henry; Jean-Pierre Marolleau; Ahmad Aljijakli; Philippe Rousselot; Pierre Fenaux; Claude Preudhomme; Sylvie Chevret; Hervé Dombret
Journal:  Lancet       Date:  2012-04-05       Impact factor: 79.321

6.  Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.

Authors:  Shigeki Ohtake; Shuichi Miyawaki; Hiroyuki Fujita; Hitoshi Kiyoi; Katsuji Shinagawa; Noriko Usui; Hirokazu Okumura; Koichi Miyamura; Chiaki Nakaseko; Yasushi Miyazaki; Atsushi Fujieda; Tadashi Nagai; Takahisa Yamane; Masafumi Taniwaki; Masatomo Takahashi; Fumiharu Yagasaki; Yukihiko Kimura; Norio Asou; Hisashi Sakamaki; Hiroshi Handa; Sumihisa Honda; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Blood       Date:  2010-08-06       Impact factor: 22.113

7.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.

Authors:  J Yates; O Glidewell; P Wiernik; M R Cooper; D Steinberg; H Dosik; R Levy; C Hoagland; P Henry; A Gottlieb; C Cornell; J Berenberg; J L Hutchison; P Raich; N Nissen; R R Ellison; R Frelick; G W James; G Falkson; R T Silver; F Haurani; M Green; E Henderson; L Leone; J F Holland
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

8.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

9.  Anthracycline dose intensification in acute myeloid leukemia.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

10.  Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study.

Authors:  H Preisler; R B Davis; J Kirshner; E Dupre; F Richards; H C Hoagland; S Kopel; R N Levy; R Carey; P Schulman
Journal:  Blood       Date:  1987-05       Impact factor: 22.113
View more
  13 in total

1.  Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia.

Authors:  Wingchi K Leung; Aster Workineh; Shivani Mukhi; Ifigeneia Tzannou; Daniel Brenner; Norihiro Watanabe; Ann M Leen; Premal Lulla
Journal:  Blood Adv       Date:  2020-01-28

2.  Drug Shortage Impacts Patient Receipt of Induction Treatment.

Authors:  Nancy G Hedlund; Zeynep Isgor; Jack Zwanziger; Damiano Rondelli; Stephanie Y Crawford; Denise M Hynes; Lisa M Powell
Journal:  Health Serv Res       Date:  2018-09-10       Impact factor: 3.402

Review 3.  Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.

Authors:  Daniel A Pollyea; Jonathan A Gutman; Lia Gore; Clayton A Smith; Craig T Jordan
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

4.  The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling.

Authors:  Youcai Deng; Jianhong Chu; Yulin Ren; Zhijin Fan; Xiaotian Ji; Bethany Mundy-Bosse; Shunzong Yuan; Tiffany Hughes; Jianying Zhang; Baljash Cheema; Andrew T Camardo; Yong Xia; Lai-Chu Wu; Li-Shu Wang; Xiaoming He; A Douglas Kinghorn; Xiaohui Li; Michael A Caligiuri; Jianhua Yu
Journal:  J Immunol       Date:  2014-08-13       Impact factor: 5.422

Review 5.  TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

Review 6.  Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Authors:  Akihiro Takeshita
Journal:  Int J Hematol       Date:  2013-05-26       Impact factor: 2.490

Review 7.  Acute myeloid leukemia and colon carcinoma during the course of acromegaly.

Authors:  Kazutaka Ozeki; Yoshihisa Morishita; Sigeki Saito; Koji Umemura; Yohei Yamaguchi; Shotaro Tatekawa; Koichi Watamoto; Akio Kohno; Tsuyoshi Nogimori
Journal:  Int J Hematol       Date:  2013-09-24       Impact factor: 2.490

8.  A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.

Authors:  Francesca Chiarini; Annalisa Lonetti; Gabriella Teti; Ester Orsini; Daniela Bressanin; Alessandra Cappellini; Francesca Ricci; Pier Luigi Tazzari; Andrea Ognibene; Mirella Falconi; Pasqualepaolo Pagliaro; Ilaria Iacobucci; Giovanni Martinelli; Sergio Amadori; James A McCubrey; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-12

9.  A Jehovah's Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions.

Authors:  Yumi Yamamoto; Akihito Kawashima; Eri Kashiwagi; Kiyoyuki Ogata
Journal:  Case Rep Hematol       Date:  2014-10-02

10.  High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy.

Authors:  Paul Brent Ferrell; Kirsten Elizabeth Diggins; Hannah Grace Polikowsky; Sanjay Ram Mohan; Adam C Seegmiller; Jonathan Michael Irish
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.